Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program (VALID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03717792|
Recruitment Status : Recruiting
First Posted : October 24, 2018
Last Update Posted : October 24, 2018
Background Vascular liver disorders (VALDI) are rare diseases, for which knowledge on risk factors, appropriate methods of diagnosis, effect of therapy and prognosis still need to be improved.
Aim of the study This project aims to study risk factors, methods of detection, therapy and prognosis in order to elaborate and disseminate updated recommendations for the optimal management of patients with VALDI.
Design of the study Data on patients will be collected from baseline (the date of diagnosis) up to 3 years. During this period, data on clinical condition, laboratory results, diagnostic tests, interventions and outcome will be collected anonymously using standardised review of medical charts by one special trained investigator. Only patients with VALDI are eligible to participate.
|Condition or disease||Intervention/treatment|
|Vascular Disorder of Liver||Other: no intervention|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program|
|Actual Study Start Date :||January 1, 2010|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||December 31, 2027|
- Other: no intervention
- Complications of Portal Hypertension [ Time Frame: up to 3 years ]Ascites, Varices, Bleeding, Encephalpathy, Thrombosis
- Mortality [ Time Frame: up to 3 years ]Survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03717792
|Contact: Michael Praktiknjo, MDemail@example.com|
|Contact: Jonel Trebicka, MD, PhDfirstname.lastname@example.org|
|University Hospital Bonn||Recruiting|
|Contact: Michael Praktiknjo, MD +49228 28715770 email@example.com|